Keryx Biopharmaceuticals — Q1 2017 Earnings Presentation
20 slides from Keryx Biopharmaceuticals's earnings presentation, May 4, 2017
Slide 1: First Quarter 2017 Financial Results
Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results May 4, 2017 Building a Leading Renal Company Exhibit 99.2
Slide 2: Agenda – First Quarter 2017 Financial Results
Agenda – First Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO 2017 Guidance & 1Q’17 Financial Results Scott Holmes, SVP and CFO Drivers of Recent Growth Tony Chambers, VP, Sales Vision & Future Growt
Slide 3: Forward-looking Statements
Forward-looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, our 2017 financial guidance and the submission of an sNDA to the FDA to expand the label of ferric citrate to include the t
Slide 4: Recent Business Highlights
Reported ~15,800 prescriptions for 1Q’17 filled at pharmacies, a 72% increase compared to 1Q’16 Provided 2017 net U.S. Auryxia product sales guidance of $56 to $60 million Secured 95% unrestricted access to Auryxia for patients on phosphate binders across Medicare Part D and commercial; removes reim
Slide 5: Financial Highlights
Financial Highlights Scott Holmes SVP and Chief Financial Officer
Slide 6: Guidance: 2017 Net U.S. Auryxia Product Sales
Guidance: 2017 Net U.S. Auryxia Product Sales Providing 2017 Auryxia guidance of $56 to $60 million, based upon: Strong 1Q prescription demand and underlying trajectory Strong prescription growth as a result of increased breadth and depth of prescribing Impact of broad formulary access: 95% of phosp
Slide 7: Strong 1Q 2017 Auryxia Prescription Demand
Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Strong 1Q 2017 Auryxia Prescription Demand +72% IMS / Specialty mix Q1 2017: 55% / 45% prescriptions
Slide 8: First Quarter 2017 Financial Highlights
First Quarter 2017 Financial Highlights ($ in millions) 1Q 2017 (unaudited) 1Q 2016 (unaudited) Net U.S. Auryxia Product Sales $ 10.5 $ 5.6 License Revenue $ 1.3 $ 1.2 Total Revenue $ 11.8 $ 6.8 Cost of Goods Sold $ 4.3 $ 1.1 Operating Expenses* $ 29.9 $ 28.4 ($ in millions) March 31, 2017 (unaudite
Slide 9: Drivers of Recent Growth
Drivers of Recent Growth Tony Chambers Vice President Sales
Slide 10: 1Q 2017 Growth in Dialysis Driven by Many Factors
Increased breadth and depth of prescribing High level of brand awareness and growing clinical familiarity, with 50% more prescribers writing in 1Q’17 vs 1Q’16 Increased yield from our prescriber interactions, with 72% increase in prescriptions, including growth in number of new Auryxia patients Mean
Slide 11: Future Growth Drivers & Vision
Future Growth Drivers & Vision Greg Madison President and Chief Executive Officer
Slide 12: Building a Leading Renal Company: Three Strategic Pathways
Building a Leading Renal Company: Three Strategic Pathways Drive and Support Keryx’s Planned Growth GROW INSPIRE Maximize Auryxia’s Potential Grow in US dialysis market Launch & grow in US IDA, NDD- CKD market Expand Portfolio Build Keryx by adding strategic assets to our portfolio Manage Growth & T
Slide 13: Near-Term Focus to Maximize Potential of Auryxia
Near-Term Focus to Maximize Potential of Auryxia Significantly more dialysis patients could benefit from treatment with Auryxia Foundation PDUFA for expanded indication 11/6/17 Strong momentum in dialysis provides solid foundation for IDA opportunity Future Opportunity ~350,000 dialysis patients on
Slide 14: Maximizing the Potential for Auryxia: IDA Opportunity
Maximizing the Potential for Auryxia: IDA Opportunity Provides Significant Leverage 95 Renal Sales Specialists Same Physician Targets Cares for 450,000 dialysis patients Cares for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicare Part D and Commercial
Slide 15: IDA, NDD-CKD Program Overview
Achievements: sNDA accepted; November 6, 2017 PDUFA target action date Completed Pivotal Phase 3 Trial: Demonstrated statistically significant differences versus placebo for the primary and all pre-specified secondary endpoints Comprehensive data of final results presented at ASN in November 2016 Ra
Slide 16: Significant Opportunity Exists to Increase Number of People Treated
Significant Opportunity Exists to Increase Number of People Treated with Auryxia ~ $2.2B Market ~$2.8B Market Market sizes are based on Auryxia dollars; Dialysis market size based on 350,000 patients, 6 tablets/day, $5.04 WAC/tablet, and a 42% gross to net adjustment. IDA near-term potential market
Slide 17: Market Insights: Need Exists for Effective, Well Tolerated IDA Treatment
Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Convenient; widely available Nephrologists report low satisf
Slide 18: Market Insights: Need Exists for Effective, Well Tolerated IDA Treatment
Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Convenient; widely available Nephrologists report low satisf
Slide 19: Key Takeaways
Key Takeaways Strong first quarter 2017 growth supports $56 - $60 million in full year 2017 net U.S. Auryxia product sales Large unmet need in iron deficiency anemia; preparing for potential launch of Auryxia for expanded indication, pending approval in November 2017 Expanded indication would provid
Slide 20: Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results
Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results May 4, 2017 Building a Leading Renal Company
Keryx Biopharmaceuticals — Q1 2017 Earnings Presentation on 6ix